β-Alanine and orotate as supplements for cardiac protection

Mark F McCarty,¹ James J DiNicolantonio²

CARNOSINE: ACID BUFFER, ANTIOXIDANT AND AID TO MUSCLE CONTRACTION

β-Alanine is a rate-limiting precursor for synthesis of the dipeptide carnosine (β-alanyl-L-histidine), which is produced within and stored in high concentrations in skeletal muscle, heart and olfactory receptor neurons.¹ ² β-Alanine supplementation has been shown to boost the carnosine content of skeletal muscle.³ This reflects the fact that the Km of carnosine synthase for β-alanine (in excess of 1 mM) is far higher than the β-alanine content of tissues; its Km for histidine is two orders of magnitude lower, such that intracellular histidine levels are not rate-limiting for carnosine synthesis.³ β-Alanine is produced in the liver during catabolism of uracil; after its release to plasma, it can be transported into tissues that require it for carnosine synthesis. Plasma levels of β-alanine also increase when carnosine is ingested in flesh foods; particularly in humans, carnosinase activity in plasma rapidly cleaves carnosine to its precursors β-alanine and histidine.⁴ The pKa of the imidazole ring of carnosine is 6.83, which makes it an ideal physiological buffer for tissues when glycolytic production of lactic acid is high.³ (The pKₐ of free histidine’s imidazole ring is around 6, so converting histidine to carnosine makes it a more effective buffer.) Most studies with supplemental β-alanine have focused on skeletal muscle and athletic performance; many studies have concluded that β-alanine supplementation can both boost muscle carnosine content and aid performance in high-intensity anaerobic workouts in which lactic acid is generated, presumably by preventing counterproductive reductions in intracellular pH.³ The fact that carnosine concentrations in fast-twitch muscles are higher than those in slow-twitch muscles is consistent with this paradigm.

Carnosine also has versatile antioxidant activity, likewise reflecting the properties of its imidazole ring. This can serve efficiently as an electron donor, preventing lipid peroxidation; it also quenches singlet oxygen and interacts with superoxide in a way that stabilises it.⁵ ⁶ Like histidine, carnosine can chelate copper and iron, and this chelation prevents these ions from catalysing Fenton chemistry, hence blocking production of hydroxyl radicals.⁷ Moreover, carnosine-copper complexes possess superoxide dismutase activity.⁷ Further, carnosine binds covalently to reactive degradation products of peroxidised lipids, preventing them from reacting with other cellular targets.⁸

Carnosine may also function in skeletal muscle and heart to amplify the impact of cytoplasmic calcium on muscular contraction.⁹ ¹⁰ It seems to do so by sensitising the contractile apparatus to free calcium; some, but not all, studies suggest that it also can upregulate calcium release from the sarcoplasmic reticulum.

BOOSTING CARDIAC CARNOSINE AS A STRATEGY FOR CARDIOPROTECTION

Cardiac muscle manufactures carnosine and related derivatives of histidine; most of these are N-acetylated.¹¹ ¹² The intracellular levels of these histidine derivatives in cardiac muscle is about 10 mM, likely reflecting a key need for their buffering activity when oxygen availability fails to meet the need for ATP production and glycolytic lactic acid production compensatorily increases. Moreover, the versatile antioxidant activity of carnosine and related histidine compounds produced in the heart also seems likely to be cardioprotective.¹³ ¹⁴ Indeed, exogenous carnosine has been shown to protect cardiac tissue from ischaemia-reperfusion damage, and is also protective for doxorubicin-induced cardiomyopathy.¹⁵–¹⁷ Further, the procontractile impact of carnosine would be of potential value in congestive failure.

It is reasonable to suspect that supplemental β-alanine would boost cardiac stores of carnosine and N-acetylcarnosine, although studies documenting this do not appear to be available. This follows from the fact that the Km for β-alanine of carnosine synthetase—known to be expressed in cardiac muscle, albeit at a lower level than in skeletal muscular
OROTATE AS A CARNOISINE PRECURSOR

Of possible pertinence is an intriguing literature documenting that supplemental magnesium orotate is clinically useful in congestive failure and angina.28-31 In particular, a placebo-controlled study evaluating magnesium orotate (6 g daily for 1 month, 3 g daily for 11 months) in patients with severe congestive failure, reported a 75.7% survival rate in the orotate treated patients, as opposed to 51.5% survival in those receiving placebo (p<0.05).31 Orotates are also beneficial in a hamster model of inherited cardiomyopathy.32 The explanation typically offered for the utility of this agent in cardiac conditions is that the stressed heart benefits from an increased pool of pyrimidine nucleotides; oral orotate is taken up by the liver and is converted to uridine, some of which reaches the plasma and can be taken up by cardiac tissue.28 33 The magnesium in this complex is also thought to benefit the failing heart.34 But why pyrimidines should be so beneficial to the heart has never been clear. This explanation is somewhat difficult to square with the observation that orotic acid supplementation only transiently and modestly increases the pyrimidine pool in the heart, yet it aids contractile recovery after global ischaemia and prevents loss of adenine nucleotides.35 Perhaps the difficulty in explaining the basis of orotate’s protective activity has resulted in this important research receiving less attention than it deserves.

As an alternative or additional explanation, it should be noted that absorbed orotate is ultimately converted to β-alanine. After orotate is employed in uridine synthesis in the liver,36 37 β-ureidopropionase and β-alanine.36 37 This β-alanine can then serve as a precursor for synthesis of carnosine in the skeletal muscle, the brain and the heart35 (see figure 1). Hence, supplementation with mineral orotates or orotic acid may represent a practical strategy for boosting the level of carnosine and carnosine derivatives within the body. Moreover, orotate may be viewed as a ‘delayed release’ form of β-alanine that may be better tolerated than β-alanine itself. Ingestion of β-alanine in doses greater than 800 mg at one time is often associated with ‘pins and needles’ paraesthesias that can last for about an hour, coinciding with an elevation of plasma β-alanine; the basis of this effect is obscure.3 30 Orotate supplementation, even in very high doses, does not seem to be attended by this problem, likely because the evolution of β-alanine proceeds gradually after orotate ingestion (timed-release β-alanine preparations can also be used to cope with this problem40).

These considerations suggest that supplemental β-alanine should be evaluated in experimental and clinical cardiac disorders, and that the role of carnosine in the documented protective effects of orotates in such conditions should be assessed. Also, since the heart makes a range of histidine derivatives other than carnosine, it would be interesting to know whether supplemental histidine might impact the cardiac level of some of these. Intriguingly, there is recent evidence that supplemental histidine may be beneficial in metabolic syndrome.41

Contributors MFM wrote the first draft. JJD reviewed and edited the manuscript.

Competing interests JJD works for a company that sells nutraceuticals but he does not profit from their sales.

Provenance and peer review Commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided...
the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

1. Boldyrev AA, Aldini G, Derave W. Physiology and pathophysiology of carnosinase. *Free Radic Res Commun* 1992;577:347–50.

2. Bonfanti L, Petretto P, De MS, et al. Carnosine-related dipeptides in the mammalian brain. *Prog Neurobiol* 1999;59:33–53.

3. Sale C, Saunders B, Harris RC. Effect of beta-alanine supplementation on muscle carnosine concentrations and exercise performance. *Am J Physiol Renal Physiol* 2010;302:F137–44.

4. Everaert I, Taes Y, De HE, et al. Low plasma carnosinase activity promotes carnosinemia after carnosine ingestion in humans. *Am J Physiol Renal Physiol* 2012;302:F137–44.

5. Kohen R, Yamamoto Y, Cundy KC, et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. *J Mol Cell Cardiol* 2008;44:927–37.

6. Pavlov AR, Revina AA, Dupin AM, et al. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. *Proc Natl Acad Sci USA* 1986;85:3175–9.

7. Kohen R, Misgav R, Ginsburg I. The SOD like activity of copper:metal-ion conjugates. *J Biol Chem* 1993;268:21603–79.

8. Baba SP, Hoetker JD, Merchant M, et al. Interaction of carnosine with superoxide radicals in water solutions. *Biochim Biophys Acta* 1993;1157:304–11.

9. Zhao Y, Zhao B. Protective effect of natural antioxidants on heart damage by singlet oxygen scavengers histidine and carnosine. *Curr Pharm Biotechnol* 2007;8:75–85.

10. Zhao Y, Zhao B. Protective effect of natural antioxidants on heart damage by singlet oxygen scavengers histidine and carnosine. *Cell Motil Cytoskelet* 2004;55:1079–87.

11. Bulygina ER, Kramarenko GG. [Isolation of carnosine synthetase from animal and human muscles]. *Vopr Med Khim* 1995;41:27–30.

12. Ozdogan K, Taskin E, Dursun N. Protective effect of carnosine on myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. *Basic Res Cardiol* 2000;95:75–83.

13. Allah SN, Bagby L, Schaffer SW. Taurine depletion, a novel mechanism for heart failure. *Am J Physiol* 1997;273(4 Pt 2):H1956–61.

14. Rosenfeld FL. Metabolic supplementation with orotic acid and magnesium orotate. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):17–52.

15. Geiss KR, Stergiou N, Jester I, et al. Effects of magnesium orotate on exercise tolerance in patients with coronary heart disease. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):153–6.

16. Branei I, Gaia D, Draguiescu I, et al. Assessment of treatment with orotate magnesium in early postoperative period of patients with cardiac insufficiency and coronary artery by-pass grafts (ATOMIC). *Rom J Intern Med* 1999;37:287–96.

17. Stepura OB, Martinov AI. Magnesium orotate in severe congestive heart failure (MACH). *Int J Cardiol* 2009;134:145–7.

18. Jasmin G, Proschek L. Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):189–95.

19. Rosenfeld FL, Richards SM, Lin Z, et al. Mechanism of cardioprotective effect of orotic acid. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):159–70.

20. Douban S, Brodsky MA, Whang DD, et al. Significance of magnesium in congestive heart failure. *Am Heart J* 1996;132:864–71.

21. Dileepan KN, Kennedy J. Rapid conversion of newly-synthesized orotate to uridine-5-monophosphate by rat liver cytosolic enzymes. *J Biol Chem* 1991;266:123–30.

22. Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in human liver. *Biochemistry* 1983;22:2533–9.

23. Jasmin G, Proschek L. Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):189–95.

24. Ito T, Kimura Y, Uek L, et al. Protective effect of natural antioxidants on heart damage by singlet oxygen scavengers histidine and carnosine. *Basic Res Cardiol* 2000;95:75–83.

25. Usui T, Kubo Y, Akanuma S, et al. Beta-alanine and L-histidine transport across the inner blood-retinal barrier: potential involvement in L-carnosine supply. *Exp Eye Res* 2013;113:135–42.

26. Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. *Basic Res Cardiol* 2000;95:75–83.

27. Bulygina ER, Kramarenko GG. [Isolation of carnosine synthetase from animal and human muscles]. *Vopr Med Khim* 1995;41:27–30.

28. Heger Z, Cernei N, Kudr J, et al. A novel insight into the cardiotoxicity of antineoplastic drug doxorubicin. *Int J Mol Sci* 2013;14:21629–48.

29. Heger Z, Cerny N, Kudr J, et al. A novel insight into the cardiotoxicity of antineoplastic drug doxorubicin. *Int J Mol Sci* 2013;14:21629–48.

30. Usui T, Kubo Y, Akanuma S, et al. Beta-alanine and L-histidine transport across the inner blood-retinal barrier: potential involvement in L-carnosine supply. *Exp Eye Res* 2013;113:135–42.

31. Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. *Basic Res Cardiol* 2000;95:75–83.

32. Allo SN, Bagby L, Schaffer SW. Taurine depletion, a novel mechanism for heart failure. *Am J Physiol* 1997;273(4 Pt 2):H1956–61.

33. Rosenfeld FL, Richards SM, Lin Z, et al. Mechanism of cardioprotective effect of orotic acid. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):159–70.

34. Dileepan KN, Kennedy J. Rapid conversion of newly-synthesized orotate to uridine-5-monophosphate by rat liver cytosolic enzymes. *J Biol Chem* 1991;266:123–30.

35. Jasmin G, Proschek L. Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):189–95.

36. Traut TW, Loechel S. Pyrimidine catabolism: individual characterization of the three sequential enzymes with a new assay. *FEBS Lett* 1983;153:1–5.

37. Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. *Cancer Res* 1985;45(11 Pt 1):5405–12.

38. Aounuma S, Hama T, Tamaki N, et al. Orotase as a beta-alanine donor for anserine and carnosine biosynthesis, and effects of actinomycin D and azauracil on their pathway. *J Biochem* 1969;66:123–32.

39. Artioli GG, Guiliano B, Smith A, et al. Role of beta-alanine supplementation on muscle carnosine and exercise performance. *Med Sci Sports Exerc* 2010;42:1162–73.

40. Decombaz J, Beaumont M, Vuichoud J, et al. Effect of slow-release beta-alanine tablets on absorption kinetics and paresthesia. *Amino Acids* 2012;43:67–76.

41. Feng RN, Niu YC, Sun XW, et al. Histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome: a randomised controlled trial. *Diabetologia* 2013;56:985–94.